Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Mayzent is a prescription sphingosine 1-phosphate receptor modulator containing siponimod. It is indicated for relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Its tablets are available in 0.25 mg, 1 mg, and 2 mg strengths.
read more about mayzent ...Siponimod binds to sphingosine 1-phosphate receptors 1 and 5. Its activity at receptor 1 reduces the release of lymphocytes from lymph nodes into the bloodstream, lowering the number of immune cells entering the central nervous system and contributing to inflammation.
Mayzent treats adults with relapsing multiple sclerosis under the approved indications. CYP2C9 genotyping is performed before treatment to determine eligibility and maintenance dose. Patients with the CYP2C9*3/*3 genotype must not receive Mayzent. Blood counts, liver tests, eye examinations, infection history, and cardiac status are assessed before treatment.
Patients with CYP2C9*1/*1, *1/*2, or *2/*2 genotypes follow a five-day dose titration before taking 2 mg once daily from day six. Patients with CYP2C9*1/*3 or *2/*3 follow a four-day titration before taking 1 mg daily from day five. Interruption of treatment can require restarting the initial titration schedule. Tablets are swallowed whole.
Serious concerns include infections, progressive multifocal leukoencephalopathy, macular edema, slow heart rate, atrioventricular conduction delays, reduced lung function, liver injury, skin cancers, and fetal harm. Severe allergic reactions, including angioedema, can occur. Eye examinations are recommended near treatment initiation, periodically during therapy, and whenever vision changes develop.
Mayzent treats relapsing multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
CYP2C9 testing determines the correct dosing schedule and identifies patients with the CYP2C9*3/*3 genotype, for whom Mayzent is contraindicated.
The maintenance dose is 2 mg or 1 mg once daily, depending on CYP2C9 genotype.
Yes. Mayzent can cause macular edema, which can impair vision and requires eye monitoring.
DailyMed - MAYZENT (siponimod) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44492772-5aed-4627-bd85-e8e89f308bb3. Date Accessed October 14, 2026.
MAYZENT (siponimod) Prescribing Information. Novartis. https://www.novartis.com/us-en/sites/novartis_us/files/mayzent.pdf. Date Accessed October 14, 2026.
Siponimod. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK553312/. Date Accessed October 14, 2026.
Siponimod. MedlinePlus. https://medlineplus.gov/druginfo/meds/a619027.html. Date Accessed October 14, 2026.
Siponimod. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Siponimod. Date Accessed October 14, 2026.